Torrent Loses US Infringement Battle Over Supernus’ Trokendi XR
Trio Of Originator Patents Protecting Topiramate Brand Will Expire In 2027
While a US district court sided with Supernus over its patent infringement claims against Torrent, the court’s opinion was sealed due to confidential and proprietary information.
You may also be interested in...
Investors rallied around shares of Supernus Pharmaceuticals in a big way on 19 August, with the company's stock soaring as high as 26.5% after the US FDA granted its approval for the Rockville, Maryland specialty pharma to market its once-daily extended release formulation of topiramate under the brand-name Trokendi XR as a treatment for patients with epilepsy.
Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.
In its latest batch of product-specific guidances, the FDA released multiple new and revised guidances on inhalers, including several on GSK’s products such as Relenza and the Ellipta trio.